Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: Results from the phase II TrINITY study

Clinical Cancer Research

Volumn 25, Issue 23, 2019, Pages 6958-6966

  Morgensztern, Daniel ^a   Besse, Benjamin ^b,c   Greillier, Laurent ^d   Santana Davila, Rafael ^e   Ready, Neal ^f   Hann, Christine L ^g   Glisson, Bonnie S ^h   Farago, Anna F ⁱ   Dowlati, Afshin ^j   Rudin, Charles M ^k   Le Moulec, Sylvestre ^l   Lally, Satwant ^m   Yalamanchili, Sreeni ^m,p   Wolf, Jurgen ⁿ   Govindan, Ramaswamy ^a   Carbone, David P ^o  

^a WASHINGTON UNIVERSITY   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e UNIVERSITY OF WASHINGTON   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l INSTITUT BERGONIÉ   (France)

^m Abbvie Stemcentrx   (United States)

ⁿ University of Cologne   (Germany)

^o OHIO STATE UNIVERSITY   (United States)

^p CytomX Therapeutics Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DELTA LIKE 3 PROTEIN; DEXAMETHASONE; DIURETIC AGENT; MEMBRANE PROTEIN; PLATINUM COMPLEX; ROVALPITUZUMAB TESIRINE; STEROID; TOPOTECAN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; BENZODIAZEPINE DERIVATIVE; DLL3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DISEASE ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOALBUMINEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PLEURA EFFUSION; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SKIN MANIFESTATION; SMALL CELL LUNG CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZODIAZEPINONES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCONJUGATES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; YOUNG ADULT;

EID: 85074276649     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-19-1133     Document Type: Article

References (31)

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539–44.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.
3. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011;378:1741–55.
4. Kalemkerian GP. Small cell lung cancer. Semin Respir Crit Care Med 2016; 37:783–96.
5. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018 doi: 10.1056/NEJMoa1809064.
6. Hanna N, Bunn PA Jr., Langer C, Einhorn L, Guthrie T Jr, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/ cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038–43.
7. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530–5.
8. Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:300–11.
9. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25: 2086–92.
10. von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014;32: 4012–9.
11. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090–6.
12. Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883–95.
13. Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet 2011;20: 905–16.
14. Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV, Matsui W, et al. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res 2009;69:845–54.
15. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015;7:302ra136.
16. Farago A, Isse K, Drapkin B, Kamesan V, Kem M, Saunders L, et al. P3.12–02 Dynamics of DLL3 and ASCL1 expression in SCLC over disease course. J Thorac Oncol 2018;13:S970–S1.
17. Geffers I, Serth K, Chapman G, Jaekel R, Schuster-Gossler K, Cordes R, et al. Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo. J Cell Biol 2007;178:465–76.
18. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017;18:42–51.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
20. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016;17:e254–e62.
21. Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 2017; 117:1736–42.
22. Hochhauser D, Meyer T, Spanswick VJ, Wu J, Clingen PH, Loadman P, et al. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res 2009;15: 2140–7.
23. Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, et al. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res 2011; 17:3794–802.
24. Simos D, Sajjady G, Sergi M, Liew MS, Califano R, Ho C, et al. Third-line chemotherapy in small-cell lung cancer: an international analysis. Clin Lung Cancer 2014;15:110–8.
25. Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, et al. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. J Thorac Oncol 2019;14:237–44.
26. Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II Study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 2018;36: 2386–94.
27. Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther 2017;180:16–23.
28. Schneider BJ, Kalemkerian GP. Personalized therapy of small cell lung cancer. Adv Exp Med Biol 2016;890:149–74.
29. Komarnitsky P, Lee H-J, Shah M, Wong S, Gulbranson S, Dziubinski J, et al. 1537TiPA phase 3 trial of rovalpituzumab tesirine vs. topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy. Ann Oncol 2017;28(suppl_5).
30. Komarnitsky PB, Lee H-J, Shah M, Wong S, Gauthier S, Dziubinski J, et al. A phase III study of rovalpituzumab tesirine maintenance therapy following first-line platinum-based chemotherapy in patients with extensive disease small cell lung cancer (ED SCLC). J Clin Oncol 2017;35(15_suppl): TPS8583.
31. Scripture C, Selvaggi G, Lakatos I, Boynton K, Lally S, Han TH, et al. 1538TiPA phase 1/2 study on safety of rovalpituzumab tesirine in combination with nivolumab or nivolumab þ ipilimumab in small cell lung cancer. Ann Oncol 2017;28(suppl_5).